Literature DB >> 17566601

To re-treat or not with gefitinib/erlotinib: This is the question for tyrosine kinase inhibitor-responsive lung cancers that progress.

Daniel B Costa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17566601     DOI： 10.1016/j.lungcan.2007.04.013

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


× No keyword cloud information.
  1 in total

1.  Post-progression survival in patients with non-small cell lung cancer with clinically acquired resistance to gefitinib.

Authors:  Hyojeong Kim; Tak Yun; Young Joo Lee; Ji-Youn Han; Heung Tae Kim; Geon Kook Lee
Journal:  J Korean Med Sci       Date:  2013-10-31       Impact factor: 2.153
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.